You have 0 items in your cart
The next major question in metabolic research may not simply be how much body weight changes.
Researchers are increasingly asking:
What type of tissue is actually being lost?
Changes in total body weight can involve both fat mass and lean body mass. This has created growing scientific interest in strategies designed to preserve skeletal muscle while metabolic interventions reduce overall body weight.
At the centre of this emerging field is a protein called myostatin.
What Is Myostatin?
Myostatin is a naturally occurring signalling protein that plays an important role in regulating skeletal muscle growth.
It belongs to the transforming growth factor-beta, or TGF-β, superfamily of proteins.
One of myostatin’s primary biological roles is essentially to act as a restraint on muscle growth.
When myostatin signalling is reduced experimentally, muscle growth can increase.
This has made the pathway an important research target in conditions involving muscle loss — and increasingly in metabolic research.
Why Is Muscle Becoming Important in Metabolic Research?
Traditional weight-management research frequently focused heavily on one measurement:
total body weight.
Researchers now have increasingly sophisticated ways to examine body composition.
This allows them to distinguish between changes in:
- fat mass
- lean mass
- visceral fat
- skeletal muscle
- bone-related measurements
This distinction matters because losing 10 kilograms of body weight doesn’t necessarily mean losing 10 kilograms of fat.
Some lean tissue can also be lost.
What Is Lean Body Mass?
Lean body mass broadly describes body tissue excluding fat.
It includes skeletal muscle, but also organs, body water and other tissues.
Consequently, lean mass and muscle mass aren’t exactly the same measurement.
However, changes in lean mass can provide researchers with useful information about what is happening to body composition during metabolic interventions.
Techniques such as dual-energy X-ray absorptiometry (DXA) are commonly used in clinical research to estimate fat and lean mass.
Why Does Lean-Mass Preservation Matter?
Skeletal muscle has functions extending well beyond movement.
It participates in:
- physical strength
- mobility
- glucose metabolism
- energy expenditure
- metabolic health
This has created interest in whether future metabolic strategies could become more selective about which tissue is lost and which tissue is preserved.
Instead of focusing exclusively on lower total body weight, researchers could potentially aim for a greater proportion of the change to come from fat tissue.
This concept is sometimes described as improving the quality of weight loss.
What Is Myostatin Inhibition?
Because myostatin normally restricts muscle growth, scientists have investigated whether reducing its activity could help preserve or increase skeletal muscle.
Different experimental approaches can interfere with the pathway.
These include antibodies and other biological molecules designed to target myostatin itself or related signalling mechanisms.
This field existed before the recent expansion of metabolic medicines.
What has changed is the possibility of combining muscle-directed research with metabolic pharmacology.
What Is Apitegromab?
Apitegromab is an investigational monoclonal antibody developed by Scholar Rock.
Rather than functioning as another appetite-regulating peptide, it targets the myostatin pathway.
Apitegromab selectively binds precursor forms of myostatin and inhibits activation of mature myostatin.
This mechanism makes it fundamentally different from GLP-1, GIP, glucagon or amylin receptor agonists.
Its original development has included research into neuromuscular conditions.
More recently, researchers have investigated whether myostatin inhibition could help preserve lean mass during pharmacologically induced weight reduction.
What Was the EMBRAZE Study?
The Phase 2 EMBRAZE study investigated this question.
Researchers enrolled 102 adults with overweight or obesity.
Participants received tirzepatide alongside either apitegromab or placebo.
Importantly, the objective wasn’t simply to determine which group lost more total weight.
Researchers specifically examined body composition.
After 24 weeks, participants receiving apitegromab had approximately 1.9 kg less lean-mass loss than the placebo group.
This represented approximately 55% relative preservation of lean mass compared with placebo.
Total body-weight changes were broadly similar between the groups.
That distinction is what makes the research particularly interesting.
Fat Loss vs Weight Loss
This introduces an important scientific distinction.
Weight loss measures the overall change on the scale.
Fat loss specifically measures changes in adipose tissue.
Two individuals could experience the same total change in body weight while undergoing substantially different changes in body composition.
One might lose proportionally more fat.
Another might lose more lean tissue.
Future metabolic research may therefore increasingly measure composition rather than simply kilograms.
Myostatin Research Is Expanding
Apitegromab isn’t the only programme investigating muscle-related pathways.
Several companies are studying myostatin and activin signalling in metabolic research.
Different experimental strategies include:
- inhibiting myostatin activation
- blocking activin receptors
- targeting multiple members of the myostatin/activin pathway
- combining muscle-directed agents with metabolic compounds
These strategies aren’t biologically identical.
That’s important because blocking different points within the pathway can potentially produce different effects.
What Is the Activin Pathway?
Myostatin belongs to a broader family of signalling molecules.
Its biological effects involve activin type II receptors.
Other molecules can also interact with these receptor systems.
This means researchers can potentially intervene at several different levels.
One approach might selectively inhibit myostatin.
Another might interfere more broadly with activin receptor signalling.
The resulting effects on muscle, fat and other tissues could differ considerably.
Bimagrumab Is Another Example
Bimagrumab provides a different approach.
Rather than selectively targeting myostatin activation, bimagrumab is an investigational antibody targeting activin type II receptors.
A 2026 Phase 2 study examined bimagrumab both independently and in combination with semaglutide.
Researchers measured total body fat and lean mass using DXA.
The combination groups showed greater preservation of lean mass than semaglutide alone while also producing substantial reductions in fat mass.
This adds to evidence that body-composition-directed pharmacology could become a significant new research category.
Could Future Metabolic Research Target Fat and Muscle Separately?
This is perhaps the most interesting possibility.
Many current metabolic compounds influence appetite, energy intake and other metabolic pathways.
Muscle-directed agents operate through very different biology.
Combining these approaches could theoretically allow researchers to investigate two separate objectives:
reducing excess fat mass
while
preserving skeletal muscle.
Whether this ultimately produces better long-term health outcomes requires considerably more research.
But scientifically, it represents a major shift.
The Scale May Become Less Important
For decades, total body weight and BMI have been dominant measurements within obesity research.
Those measurements remain useful, but they don’t reveal everything about body composition.
Modern imaging and body-composition technologies allow researchers to ask more detailed questions.
How much fat changed?
How much visceral fat changed?
How much lean tissue changed?
Was skeletal muscle preserved?
These measurements could become increasingly important as metabolic treatments become more powerful.
Why Myostatin Research Is Worth Watching
Myostatin research represents a genuinely different direction from simply developing another incretin compound.
Instead of asking how to increase total weight reduction, researchers are beginning to ask whether they can change the composition of that reduction.
Apitegromab and other muscle-directed programmes provide early examples.
The concept remains experimental, and larger studies will be needed to establish whether preserving lean mass translates into meaningful improvements in strength, physical function and long-term outcomes.
But the direction of research is significant.
The next generation of metabolic science may increasingly focus not only on how much changes — but what changes.
Research Notice: Apitegromab, bimagrumab and other compounds discussed in this article are investigational in the contexts described. This article is provided for scientific and educational purposes only and does not provide medical advice, treatment recommendations or dosing guidance.